stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) Current ratio
IDEAYA Biosciences, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 9.0×, down 2.3× from fiscal 2025 (11.3×). Over the past ten years it has ranged from 5.6× (fiscal 2021) to 19.7× (fiscal 2023); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 11.3× | (24.28%) |
| FY2024 | 15.0× | (23.83%) |
| FY2023 | 19.7× | 68.27% |
| FY2022 | 11.7× | 110.14% |
| FY2021 | 5.6× | (25.59%) |
| FY2020 | 7.5× | (49.01%) |
| FY2019 | 14.6× | (12.55%) |
| FY2018 | 16.7× | 200.31% |
| FY2017 | 5.6× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 9.0× | (13.45%) |
| Jun 2026 | 10.5× | (2.67%) |
| Mar 2026 | 10.7× | (5.28%) |
| Dec 2025 | 11.3× | (8.89%) |
| 27 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 64.1× |
| VRDN Viridian Therapeutics, Inc. compare | 14.5× |
| BEAM Beam Therapeutics Inc. compare | 13.0× |
| DYN Dyne Therapeutics, Inc. compare | 12.0× |
| IDYA IDEAYA Biosciences, Inc. | 9.0× |
| CELC Celcuity, Inc. compare | 8.9× |
| DNLI Denali Therapeutics Inc. compare | 6.2× |
| TLX Telix Pharmaceuticals Limited compare | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement